Thyroid Gland Follicular Carcinoma

In conclusion, TFHL-associated B/PCP are a heterogeneous group of lymphoproliferative and plasma cell disorders, displaying recurrent histological patterns and frequent clonal hematopoiesis-associated mutations. Further studies on larger cohorts of patients are warranted to elucidate their biological and clinical implications.

Thyroid bed FNA is a reliable method for detecting recurrent thyroid carcinoma, showing 100% cytohistologic concordance for TBS III and above. Tg is not universally elevated in recurrent tumors (sensitivity 57%), but an increased Tg level in the setting of nondiagnostic FNA warrants further evaluation. The 27% rate of unsatisfactory specimens likely reflects postsurgical scarring, which can clinically mimic recurrence.

Furthermore, the effects of the covalent DNMT inhibitor, 5-azacytidine (5-Aza), and the DNMT1-selective inhibitor, GSK-3484862, on cell viability were evaluated in PTC and follicular thyroid carcinoma (FTC) cell lines...Sustained inhibition of DNMT1 effectively reduced global DNA methylation and promoted apoptosis, highlighting the potential of prolonged DNMT1-targeted therapy. Further in vitro and in vivo studies are warranted to validate these results and elucidate the underlying mechanisms.

We identified distinct clinical and histologic features, as well as differential PD-Ll expression between cFDCS and EBV + IFDCS, supporting their classification as separate entities. Further molecular studies are needed to investigate their pathogenesis.

HTR0 is unrelated to the disease burden (thyroglobulin and metastasis) and histopathological variant. High HTR0 is associated with poor response and residual disease. Rising HTR in follow-up also signifies the inadequate response to RIT. HTR acts as a supplementary tool to existing risk factors, and thyroglobulin for predicting therapeutic response in DTC.

In each molecular category, secondary alterations can occur; most notably TERT promoter and TP53 mutations occur with increasing frequency in high-grade differentiated, poorly differentiated, and anaplastic thyroid carcinomas. This article will review the diagnostic, prognostic, and therapeutic significance of molecular alterations across the spectrum of follicular cell derived thyroid tumors and discuss strategies for investigating unusual molecular alterations encountered in clinical practice.

The story has come full circle, and the recent proposal to incorporate FVPTC into follicular adenoma is in keeping with Lindsay's original concept. By the current understanding, these nuclei are classified better by molecular associations.

P=N/A, N=1200, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P=N/A, N=90, Completed, Tianjin First Central Hospital; Tianjin First Central Hospital

P=N/A, N=20, Not yet recruiting, Mayo Clinic

Taken together, our results indicate that KLK7 is overexpressed in thyroid cancer and is linked to disease progression and dedifferentiation, partly by disrupting cell adhesion networks. KLK7 may therefore serve as a biomarker for aggressive thyroid cancer and a potential therapeutic target.

This approach has the potential to improve diagnostic accuracy, reduce unnecessary surgical interventions, and enhance patient outcomes. Future research should focus on standardizing procedures and conducting large-scale validation studies.